The details, compiled in a White House fact sheet, were shared first with CNN.
In a briefing Thursday morning alongside HHS Secretary Xavier Becerra and CDC director Dr. Rochelle Walensky, White House monkeypox response coordinator Bob Fenton announced, “We have accelerated phase four of our national vaccine strategy. Starting Monday, an additional 1.8 million doses of vaccine will be available to jurisdictions for ordering.” That accelerated allocation phase will give states and jurisdictions more visibility into how much of the vaccine to expect as they make plans to distribute it.
The Biden administration is also providing more resources to local jurisdictions to help transition to the new type of injection to stretch out vaccine supply. The administration is encouraging states to provide the Jynneos vaccine intradermally — or between the layers of the skin — rather than subcutaneously, or under the skin, which would allow providers to stretch out the supply in one standard-dose vial. Los Angeles County in California and Fulton County in Georgia have both switched completely over to the intradermal vaccine, a White House official told CNN, as the administration is “providing technical assistance, support and resources to jurisdictions in the process of adopting and expanding intradermal administration.”
“HHS is launching a pilot program that will provide up to 50,000 doses from the national stockpile to be made available for pride and other events that will have high attendance of gay and bisexual men,” Fenton said Thursday, calling it an “important” and “innovative” way to bolster local efforts to mitigate spread.
One of the upcoming events is the Charlotte Pride Festival and Parade this weekend in North Carolina. Officials acknowledge that this effort will not prevent spread around these events since the vaccine does not provide full immunity until two weeks after the second dose. But it is an effort to raise awareness and meet people where they are.
The CDC is also “offering assistance and support to jurisdictions to prepare for these large events, including helping develop vaccine and testing strategies to be stood up in and around these events, developing tools for information-gathering from event participants, and providing messaging and communications resources on vaccines, testing, and strategies to reduce one’s risk of contracting the virus,” the White House fact sheet said.
“Next week, HHS will be pre-positioning 50,000 courses of Tpoxx across the country. That’s nearly five times as many treatment courses than confirmed cases in the US. These courses will be made available to jurisdictions where the outbreak is most severe so that individuals can get treatment more quickly from their healthcare providers,” Fenton said.
Dawn O’Connell, HHS assistant secretary for preparedness and response, said the new effort reflects that “this is not a static response. We are continuing to assess where we are, evaluate what we need and make improvements in real time.” The Biden administration has faced criticism that it was slow to respond to the evolving outbreak.
The allocation will rely on a formula based 75% on the number of cases in a jurisdiction and 25% on the number of individuals at risk.
“It’s important that we all take monkeypox seriously, and it’s critical that we do all we can to keep this dangerous virus from spreading here,” Becerra told reporters Thursday, adding that there was “more work to do.”
US federal health officials also said the alternative method of administering smaller doses of the Jynneos monkeypox vaccine through intradermal injection would provide some protection as the nation continues to battle the virus.
Yet on the topic of exact efficacy numbers, Walensky said: “We don’t yet know how well this vaccine will work in this outbreak.”
CNN has reported that Jynneos has been approved for emergency purposes based on studies of immune responses, not clinical outcomes, because there haven’t been smallpox or monkeypox outbreaks large enough to test it.
The US Food and Drug Administration last week issued an emergency use authorization allowing the Jynneos monkeypox vaccine to be injected into the skin, a shift that can stretch the supply of vaccines as it would require a fifth of a dose used for a subcutaneous injection. The FDA said it based the authorization on a 2015 clinical study of intradermal injection compared with subcutaneous, finding that they produced similar results.
“So, when the strategy for intradermal dosing, which we anticipate will work just as well as subcutaneous dosing, we again met closely with health departments,” Walensky said. “This has been fluid, but we have been in close touch with our state and local health departments providing them all the data and all the information that we have when we have it.”
Dr. Peter Marks, the director of the FDA’s Center for Biologics and Evaluation Research, said the shift to intradermal injection was made “very carefully” and “with a lot of thought.”
“We are working very actively to make sure that the community has the information that we reviewed and can see the thought process that we use to come to the conclusion that giving this intradermally provided the same kind of protection as giving it by the subcutaneous route,” Marks said.
Dr. Demetre Daskalakis, the White House’s assistant monkeypox response coordinator, said, “It’s safe, it’s equally effective, and also allows us to expand extend vaccine so that we can maximize protection in the community. “
This story has been updated with additional reaction.
CNN’s Deidre McPhillips contributed to this report.